New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.

@article{Kurzeja2011NewIP,
  title={New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.},
  author={Marta Kurzeja and Lidia Rudnicka and Malgorzata Olszewska},
  journal={American journal of clinical dermatology},
  year={2011},
  volume={12 2},
  pages={113-25}
}
Interleukin (IL)-23 is an important regulator of T helper-17 lymphocytes, which influence the cutaneous immune system by production of IL-17 and several other proinflammatory cytokines. This pathway has been recently linked to the pathogenesis of psoriasis and numerous other skin diseases. A newly developed biologic drug, ustekinumab (CNTO-1275), which targets the p40 subunit of IL-12 and IL-23, was approved by the US FDA and the European Medicines Agency in 2009 for the treatment of moderate… CONTINUE READING